[go: up one dir, main page]

GB202408599D0 - Combination treatments - Google Patents

Combination treatments

Info

Publication number
GB202408599D0
GB202408599D0 GBGB2408599.5A GB202408599A GB202408599D0 GB 202408599 D0 GB202408599 D0 GB 202408599D0 GB 202408599 A GB202408599 A GB 202408599A GB 202408599 D0 GB202408599 D0 GB 202408599D0
Authority
GB
United Kingdom
Prior art keywords
combination treatments
treatments
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2408599.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasopharma AB
Original Assignee
Vasopharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasopharma AB filed Critical Vasopharma AB
Priority to GBGB2408599.5A priority Critical patent/GB202408599D0/en
Publication of GB202408599D0 publication Critical patent/GB202408599D0/en
Priority to PCT/EP2025/066653 priority patent/WO2025257422A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2408599.5A 2024-06-14 2024-06-14 Combination treatments Ceased GB202408599D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2408599.5A GB202408599D0 (en) 2024-06-14 2024-06-14 Combination treatments
PCT/EP2025/066653 WO2025257422A1 (en) 2024-06-14 2025-06-13 Combination treatments of mek and pkc inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2408599.5A GB202408599D0 (en) 2024-06-14 2024-06-14 Combination treatments

Publications (1)

Publication Number Publication Date
GB202408599D0 true GB202408599D0 (en) 2024-07-31

Family

ID=91961139

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2408599.5A Ceased GB202408599D0 (en) 2024-06-14 2024-06-14 Combination treatments

Country Status (2)

Country Link
GB (1) GB202408599D0 (en)
WO (1) WO2025257422A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013352379B2 (en) * 2012-11-29 2018-09-06 Novartis Ag Pharmaceutical combinations
TW201819625A (en) * 2016-08-23 2018-06-01 中央研究院 Method for preparing induced mesenchymal stem cells and improving mesenchymal stem cell's characters and its applications
WO2023150702A2 (en) * 2022-02-03 2023-08-10 The Johns Hopkins University Compositions and methods for treatment of connective tissue disorders

Also Published As

Publication number Publication date
WO2025257422A1 (en) 2025-12-18

Similar Documents

Publication Publication Date Title
IL316750A (en) Treatments with nirogacestat
GB202408599D0 (en) Combination treatments
GB202408598D0 (en) Combination treatments
GB202500804D0 (en) Treatments
GB202505461D0 (en) New combination treatments
GB202501437D0 (en) New treatments
GB202416580D0 (en) New treatments
GB202503757D0 (en) Novel treatments
GB202403681D0 (en) Novel treatments
GB202208911D0 (en) Treatments
GB202405551D0 (en) Combination treatment
GB202510767D0 (en) Combination therapy
GB202416518D0 (en) Combination therapy
GB202416133D0 (en) Combination therapy
GB202408292D0 (en) Combination therapy
GB202403748D0 (en) Combination therapy
GB202510723D0 (en) Treatment
GB202509233D0 (en) Treatment
GB202507490D0 (en) Treatment
GB202505840D0 (en) Treatment
GB202505122D0 (en) Treatment
GB202505019D0 (en) Treatment
GB202503458D0 (en) Treatment
GB202415981D0 (en) Treatment
GB202415982D0 (en) Treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)